USPTO serial 88507409
MEDPOINT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 23, 2021
- Examiner
- CASE, LEIGH CAROLINE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with MEDPOINT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $548*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Evanston, IL, US
Evanston, IL, US
Evanston, IL, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John L. Ambrogi
John L. Ambrogi LATIMER LEVAY FYOCK LLC55 West Monroe StreetSuite 1100Chicago, IL 60603Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 041 | Training and support services, namely, live digital training events, web site-based training modules, and web site-based training management center featuring instruction in the field of digital media support for clinical research; and training clinical research raters in the use of digital and web site-based systems | ACTIVE | Aug 29, 2011 |
| 042 | Providing digital technology services, namely, Software as a Service services featuring a software platform for providing users access to documents, training, messages, alerts, forms, and related materials in the field of medical and scientific research information and clinical trials, and computer services that provide web facilities, namely, a web-based system in the nature of online non-downloadable software and online portal in the field of medical and scientific research information and clinical trials that provides users access to documents, training, messages, alerts, forms, and related materials; hosting secure, audit-ready compliant online web facilities for others for organizing and conducting online meetings, gatherings, and interactive discussions for the biopharma industry, namely, providing a website featuring technology that enables clinical research associates to monitor investigative sites that are conducting clinical trials by means of live virtual meetings; providing an online non-downloadable live virtual meeting software platform to support remote, digital patient visits to investigator sites in the course of clinical trials for medicines and medical products by providing a website with technology that allows health care professional speakers to hold digital online meetings for virtual events over the internet, that allows users to hold virtual speaking events and advisory and pharmaceutical webcasts, that allows health care professionals to conduct virtual and online digital advisory and consulting meetings, that allows uses to conduct virtual and online digital pharmaceutical and biotech training events, that allows uses to conduct and online digital speaking and virtual peer-to-peer programs; providing online non-downloadable computer software for document management processes for product marketing, commercialization, medical affairs and clinical research for medical product, pharmaceutical and biotechnology companies, for clinical trial document and records exchange and access which includes providing a hosted website portal in the nature of an online computer database featuring online information in the field of healthcare for use by healthcare professionals engaged in commercialization of medical products; providing online non-downloadable software for providing access to a portal that provides patients with information regarding clinical trials and allows them to stay connected and in control of their role as participants in clinical trials; providing support services, namely, computer programming, customizing computer software, system analysis and design for document management processes for product marketing, commercialization, medical affairs and clinical research, for medical product, pharmaceutical and biotechnology companies | ACTIVE | Jul 6, 2011 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Medpoint Communications, Inc.
- Other trademarks owned by Medpoint Communications, Inc.
- Other trademarks owned by Medpoint Communications, Inc.
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named MEDPOINT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 2, 2026 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Feb 23, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Feb 23, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 19, 2021 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jan 18, 2021 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jan 8, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 7, 2021 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jan 7, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 4, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 15, 2020 | IUAF | USE AMENDMENT FILED | — |
| Dec 15, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 15, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 15, 2020 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jun 16, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 21, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 21, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 1, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 13, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 10, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 10, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 10, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 10, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 20, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 20, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 20, 2020 | ALIE | ASSIGNED TO LIE | — |
| Feb 14, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 14, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 26, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 17, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 13, 2019 | NWAP | NEW APPLICATION ENTERED | — |